Delivery Order SPE2DB24D2205-SPE2DB25FEGSK
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector units. This firm fixed-price delivery order, valued at $6,863.64, represents a competitive award with no set-aside designation and is scheduled for completion by August 21, 2025. The award was issued to AmerisourceBergen's Corporate Office division, with performance to take place at the company's...
- The Defense Logistics Agency awarded a delivery order valued at $12,326.27 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL auto-injectors. This firm fixed price, non-set-aside contract was awarded on August 22, 2025, with an ultimate completion date of August 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Actemra is a biologic immunosuppressant medication used primarily to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a $5,755.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This is a non-set-aside, competitively awarded contract with performance completion targeted for August 12, 2025, with fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader...
- The U.S. Department of Defense Medical Supply Chain awarded a $6,235.68 delivery order to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $18,202.15 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors. This firm fixed price delivery order, awarded on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a competitive award with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting the company's role as a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,791.56 for ACTEMRA ACTPEN 162 mg/0.9 mL auto-injector pens on August 11, 2025, with performance completion scheduled for August 12, 2025. This firm fixed price delivery order represents a non-set-aside, competitively awarded contract with no small business or other socioeconomic preferences applied. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $38,677.92 to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 mL auto-injectors. This firm fixed-price delivery order, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-competitive award under the company's existing indefinite delivery contract with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $32,838.00 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. The contract, executed on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,058.52 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL injectable medication. Issued on August 14, 2025, with an ultimate completion date of August 15, 2025, this firm fixed-price contract requires performance at the company's Conshohocken, Pennsylvania location. The award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet...
- The Defense Logistics Agency awarded a delivery order valued at $19,253.01 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL pharmaceutical supplies. The contract, executed on August 5, 2025, with an ultimate completion date of August 6, 2025, utilizes firm fixed pricing and represents a non-set-aside competitive award. Performance will be conducted at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEGSKDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector pens with a ceiling value of $12,969.00 and firm fixed pricing. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 25, 2025. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a primary pharmaceutical distributor for federal medical procurement, with particular focus on military and veteran healthcare systems. The company supplies a broad range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. Actemra is a biologic immunosuppressant used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the company's role in providing critical specialty medications to federal healthcare customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.0k | 8/22/25 |